Firebrick Pharma Limited (ASX:FRE)

Market Cap	14.82M
Revenue (ttm)	1.13M
Net Income (ttm)	-1.72M
Shares Out	224.58M
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	13
Average Volume	30,108
Open	0.0660
Previous Close	0.0660
Day's Range	0.0660 - 0.0660
52-Week Range	0.0450 - 0.1000
Beta	1.49
RSI	39.58
Earnings Date	May 21, 2025

About Firebrick Pharma

Firebrick Pharma Limited engages in the development and commercializing of novel formulations for the uses of povidone iodine in Australia. The company offers broad-spectrum antimicrobial nasal spray for the treatment of common cold under the Nasodine name. It also operates in the United states and Singapore. Firebrick Pharma Limited was incorporated in 2012 and is based in Melbourne, Australia.

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 2012
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: FRE

Financial Performance

In 2024, Firebrick Pharma's revenue was 2.75 million, an increase of 12096.48% compared to the previous year's 22,550. Losses were -1.18 million, -82.71% less than in 2023.